Table 5.
Prevalences of BRCA1/2 germline mutations between non‐Ashkenazi individuals and Japanese
| Group | Subgroup | Prevalence of mutations in BRCA1/2 | P‐values* | Odds ratio (95% CI)* | |
|---|---|---|---|---|---|
| Non‐Ashkenazi individuals (Myriad)( 6 ) | Japanese (FALCO) | ||||
| I | I‐1 | 4/172 (2.3%) | 3/14 (21.4%) | 0.010 | 11.11 (1.450–75.21) |
| I‐2 | 55/579 (9.5%) | 4/26 (15.4%) | 0.307 | 1.730 (0.418–5.360) | |
| I‐3 | 5/77 (6.5%) | 0/2 (0%) | ND | ND | |
| II | II‐1 | 34/315 (10.8%) | 2/16 (12.5%) | 0.689 | 1.180 (0.125–5.491) |
| II‐2 | 206/806 (25.6%) | 13/33 (39.4%) | 0.103 | 1.892 (0.848–4.079) | |
| II‐3 | 25/67 (37.3%) | 0/1 (0%) | ND | ND | |
| II‐4 | 4/87 (4.6%) | 0/5 (0%) | ND | ND | |
| II‐5 | 41/236 (17.4%) | 4/11 (36.4%) | 0.119 | 2.704 (0.554–11.22) | |
| II‐6 | 35/111 (31.5%) | 1/6 (16.7%) | 0.665 | 0.437 (0.009–4.112) | |
| II‐7 | 19/87 (21.8%) | 1/3 (33.3%) | 0.534 | 1.776 (0.029–35.87) | |
| III | – | 10/52 (19.2%) | 1/1 (100%) | ND | ND |
| IV | IV‐1 ‡ | 16/39 (41.0%) | 0/0 | ND | ND |
| IV‐2 | 9/20 (45.0%) | 1/1 (100%) | ND | ND | |
| IV‐3 | 126/267 (47.2%) | 3/5 (60%) | 0.671 | 1.675 (0.189–20.35) | |
| IV‐4 ‡ | 38/71 (53.5%) | 0/0 | ND | ND | |
| IV‐5 | 16/24 (66.7%) | 1/1 (100%) | ND | ND | |
| V | V‐1 | NR | 0/0 | ||
| V‐2 | NR | 0/0 | |||
| V‐3 | NR | 0/0 | |||
| V‐4 | NR | 0/0 | |||
| V‐5 | NR | 1/4 (25.0%) | |||
| V‐6 | NR | 1/6 (16.7%) | |||
| Subtotal for Group I | 64/828 (7.7%) | 7/42 (16.7%) | 0.0471 † | 2.613 (1.108–6.162) † | |
| Subtotal for Group II | 364/1709 (21.3%) | 21/75 (28.0%) | 0.134 † | 1.554 (0.915–2.640) † | |
| Subtotal for Group IV | 151/311 (48.6%) | 5/7 (71.4%) | 0.455 † | 2.589 (0.484–13.87) † | |
| Subtotal for Group V | NR | 2/10 (20.0%) | ND | ND | |
| Total for Groups I–IV | 589/2900 (20.3%) | 34/125 (27.2%) | 0.005 † | 1.873 (1.217–2.884) † | |
*
Fisher's exact test.
†
† Estimated by Mantel‐Haenszel test.
‡
‡ Excluded from Mantel‐Haenszel test due to the absence of enrolled subjects. CI, confidence interval; ND, not done.